CIP
UTHR icon

Convergence Investment Partners’s United Therapeutics UTHR Stock Holding History

Convergence Investment Partners’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-1,725
Closed -$289K – 285
2021
Q1 		$289K Buy
+1,725
New +$288K 0.13% 159
2020
Q4 		– Sell
-9,575
Closed -$967K – 284
2020
Q3 		$967K Buy
9,575
+5,367
+128% +$589K 0.34% 110
2020
Q2 		$509K Buy
+4,208
New +$473K 0.18% 173
2018
Q4 		– Sell
-6,754
Closed -$864K – 373
2018
Q3 		$864K Buy
6,754
+2,294
+51% +$284K 0.18% 163
2018
Q2 		$505K Buy
4,460
+4,311
+2,893% +$474K 0.07% 259
2018
Q1 		$17K Buy
+149
New +$18.9K ﹤0.01% 627
2017
Q3 		– Sell
-17,230
Closed -$2.23M – 399
2017
Q2 		$2.23M Sell
17,230
-656
-4% -$81.8K 0.33% 115
2017
Q1 		$2.42M Buy
17,886
+86
+0.5% +$13K 0.34% 114
2016
Q4 		$2.55M Buy
17,800
+9,220
+107% +$1.18M 0.35% 105
2016
Q3 		$1.01M Buy
8,580
+6,486
+310% +$779K 0.15% 238
2016
Q2 		$222K Sell
2,094
-22,365
-91% -$2.49M 0.03% 302
2016
Q1 		$2.73M Buy
24,459
+3,334
+16% +$422K 0.32% 108
2015
Q4 		$3.31M Buy
21,125
+5,150
+32% +$750K 0.37% 98
2015
Q3 		$2.1M Buy
15,975
+7,325
+85% +$1.17M 0.24% 147
2015
Q2 		$1.5M Buy
+8,650
New +$1.56M 0.15% 220
2014
Q3 		– Sell
-10,760
Closed -$952K – 430
2014
Q2 		$952K Buy
+10,760
New +$1.03M 0.13% 244
2014
Q1 		– Sell
-30,555
Closed -$3.46M – 434
2013
Q4 		$3.46M Sell
30,555
-580
-2% -$52.3K 0.56% 36
2013
Q3 		$2.46M Buy
31,135
+4,435
+17% +$324K 0.52% 51
2013
Q2 		$1.76M Buy
+26,700
New +$1.72M 0.46% 72

Other funds holding UTHR

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Convergence Investment Partners's UTHR Position: Q2 2021 in Review

Convergence Investment Partners sold out of United Therapeutics (UTHR) in Q2 2021, closing a stake of 1,725 shares — an estimated $289K sold.

Convergence Investment Partners first reported a position in UTHR in Q2 2013 and held it in 19 quarters. The position peaked at $3.46M in Q4 2013. 402 funds tracked by Wall St. Rank hold UTHR as of Q2 2021.

  • Convergence Investment Partners reported no remaining United Therapeutics position as of Q2 2021 after selling out during the quarter.
  • Convergence Investment Partners sold 1,725 United Therapeutics shares in Q2 2021, an estimated $289K.
  • Convergence Investment Partners first reported a position in United Therapeutics in Q2 2013 and held it in 19 quarters.
  • Convergence Investment Partners's United Therapeutics position peaked at $3.46M in Q4 2013.
  • 402 funds tracked by Wall St. Rank held United Therapeutics as of Q2 2021.

Based on Convergence Investment Partners's 13F filing for Q2 2021, filed 19 Jul 2021.